Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Aim of this study is to determine wether the macromolecular spectral characteristic of
ulcerative colitis patients - measured by Physiological Intermolecular Modification
Spectroscopy (PIMS) - is a predictive factor for response to Simponi treatment